MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
9.67
-0.30
-3.01%
Opening 11:06 01/08 EST
OPEN
9.83
PREV CLOSE
9.97
HIGH
9.91
LOW
9.60
VOLUME
196.24K
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
5.41
MARKET CAP
841.46M
P/E (TTM)
-3.9023
1D
5D
1M
3M
1Y
5Y
1D
BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 3d ago
Kura Oncology Grants Stock Options to New Employees Under Inducement Plan
Reuters · 3d ago
Weekly Report: what happened at KURA last week (1229-0102)?
Weekly Report · 3d ago
Weekly Report: what happened at KURA last week (1222-1226)?
Weekly Report · 12/29/2025 09:27
Kura Oncology rises following Jim Cramer comments
Seeking Alpha · 12/22/2025 17:01
2025 Performance Review And Future Strategy
Seeking Alpha · 12/22/2025 13:30
Weekly Report: what happened at KURA last week (1215-1219)?
Weekly Report · 12/22/2025 09:27
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
NASDAQ · 12/22/2025 04:20
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.